GALEAS™ Bladder, our urine test for the non-invasive detection and monitoring of bladder cancer, has appeared in the European Association of Urology (EAU) Guidelines on Non-Muscle-Invasive Bladder Cancer in a surveillance setting.
The Guidelines are developed by the EAU as best practice clinical guidelines primarily for frontline urologists across Europe, but also for patients to support shared decision making.
GALEAS Bladder delivers high sensitivity for the detection of bladder cancer recurrence. The urine test can also detect bladder cancer before the disease is visible via cystoscopy, offering hope that recurrences can be treated earlier, and that patients can undergo fewer invasive cystoscopies while in surveillance.
Co-developed by Professor Rik Bryan and Dr Doug Ward at the University of Birmingham with Cancer Research UK funding, GALEAS Bladder is a genetic bladder cancer test that analyses urine samples collected by patients either at home or in the clinic. It is currently being evaluated by NHS Trusts in a triage setting, with growing excitement about its potential to reduce the number of cystoscopies performed.
Professor Rik Bryan, Director of the Bladder Cancer Research Centre at the University of Birmingham, comments: “We are delighted that GALEAS Bladder is now included in the EAU Guidelines for Non-Muscle-Invasive Bladder Cancer as one of the urinary molecular markers shown to have high sensitivity to detect tumour recurrence, particularly in high grade disease. It also shows a very high negative predictive value to make the premise for the test's future implementation in follow-up or surveillance of non-muscle-invasive bladder cancer patients1.
“The Guidelines highlight that GALEAS Bladder has extremely high sensitivity for the detection of any bladder cancer recurrence (86%) and exceptional sensitivity for the detection of high-grade recurrence (100%) based upon the findings from our 2023 study of 293 patients2.
Jeff Bousfield, CEO of Nonacus, comments: “This is an important milestone for our GALEAS Bladder test, with its proven high sensitivity and specificity having the potential to bring patient-advocated improvements into clinical practice. Our inclusion into these Guidelines makes it easier for clinicians across Europe to adopt GALEAS Bladder, helping more bladder cancer patients to benefit from our easy, simple and accurate test without the need for an invasive procedure.”
